1. Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339–57.
2. Network NCC. NCCN clinical practice guidelines in oncology: non small cell lung cancer (version 7.2024). 2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 10 July 2024.
3. PR Newswire. Ivonescimab in combination with chemotherapy approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A clinical trial: positive trend observed in overall survival towards ivonescimab plus chemotherapy [media release]. 1 June 2024. https://www.prnewswire.com/news-releases/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy-302161109.html.
4. Akeso Biopharma. Ivonescimab (依达方): Chinese prescribing information. Zhongshan City: Kangfang Sino Pharmaceutical Co; 2024.
5. Akeso Biopharma. Akeso Inc. announces collaboration and license agreement for up to US$5 billion with Summit Therapeutics to accelerate global development and commercialization of its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF) [media release]. 6 Dec 2022. https://www.akesobio.com/en/media/akeso-news/20221206/.